| Literature DB >> 34152898 |
Patrice Chevallier1,2, Soraya Saiagh3, Virginie Dehame2, Thierry Guillaume1,2, Pierre Peterlin1, Sylvain Bercegeay3, Yannick Le Bris4, Céline Bossard5, Isabelle Gauvrit6, Brigitte Dreno3, Nadine Juge-Morineau1, Marie C Béné2,4, Marc Gregoire2.
Abstract
This was a phase I/II study testing the feasibility of a vaccine by autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) in elderly acute myeloid leukemia (AML) patients in first or second complete remission. Pulsed DC were administered at doses of 9 × 106 subcutaneously (1 mL) and 1 × 106 intra-dermally (0.1 mL). Five doses of vaccine were planned on days +1 + 7 + 14 + 21 and +35. Five DC-vaccines were produced and injected for all five patients included in the study. No severe adverse event was documented. Larger Phase 2 studies are now required to precise the role of DC-vaccines with leukemic apoptotic bodies in older as well as younger AML populations. (Clinicaltrials.gov NCT01146262).Entities:
Keywords: AML; Dendritic cells; apoptotic corpses; vaccine
Mesh：
Substances：
Year: 2021 PMID： 34152898 PMCID： PMC8437462 DOI： 10.1080/21645515.2021.1943991
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 4.526